About OmniSeq
OmniSeq is a company based in Buffalo (United States) founded in 2015. OmniSeq has raised $8.89 million across 5 funding rounds from investors including LabCorp and Hitachi High-Tech Corporation. OmniSeq offers products and services including OmniSeq INSIGHT. OmniSeq operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
- Total Equity Funding$8.89M (USD)
in 5 rounds
- Latest Funding Round$1.57M (USD), Series B
Jun 2019
- InvestorsLabCorp
& 1 more
Products & Services of OmniSeq
OmniSeq offers a comprehensive portfolio of products and services, including OmniSeq INSIGHT.
Comprehensive profiling for solid tumors to guide precision oncology treatments.
Apps and channels of OmniSeq
its YouTube channel Labcorp has 6.37K subscribers and 30 videos.
Videos from OmniSeq
The most watched videos on OmniSeq's YouTube channel, Labcorp (6.37K subscribers). Click a video to play it here.
More on Labcorp .
Funding Insights of OmniSeq
OmniSeq has successfully raised a total of $8.89M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $1.57 million completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.89M
- Total Rounds 5
- Last Round Series B — $1.57M
- First Round $10M
(Aug 2017)
- Investors Count 2
All 5 funding rounds of OmniSeq with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2019 | $1.57M | Series B | – | – | – |
| May 2019 | $7.33M | Series B | – | – | – |
| Apr 2018 | – | Series B | – | Hitachi High-Tech Corporation | – |
| Aug 2017 | – | Series B | – | – | |
| Aug 2017 | $10M | Debt – Conventional | – | – | – |
2 investors in total: 2 institutional.
Investors in OmniSeq
OmniSeq has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include LabCorp and Hitachi High-Tech Corporation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Operations are maintained across multiple industries by the diversified conglomerate. | 1947 | hitachi-hightech.com | Minato City, Japan | |
Provider of laboratory tests for physicians | 1969 | labcorp.com | Burlington, United States |
Investor details for OmniSeq
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of OmniSeq
8 people are tracked at OmniSeq (4 in leadership, 4 in team).
| Name | Role | Group |
|---|---|---|
Paul DePietro | Executive Director, Knowledge Informatics | Leadership |
William Stoll | Senior Director, Regulatory Affairs & Quality Assurance | Leadership |
Shengle Zhang | Senior Director & Laboratory Director | Leadership |
Sarah Howarth | Executive Director of Payer and Client Relations | Leadership |
Ann Richardson | Quality Systems Manager | Team |
Tammy Roalsvig, MA, CAPM, LSSGB-H | Scientific Project Manager | Team |
Brandon Biskup | Accounting Manager | Team |
Erin DeBlasi | Research And Development Scientist | Team |
Complete people profiles for OmniSeq
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of OmniSeq
3 dated milestones of OmniSeq across 4 years, from founding to its latest funding, stage changes and deals.
- Founded OmniSeq is founded.
- Funding First funding round of $10.0M.
- Funding Latest funding round, Series B, of $1.6M.
Competitors of OmniSeq
OmniSeq operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| cernostics.com | 2008 | Pittsburgh, United States | $14.18M | 16 | Precision diagnostic and prognostic tests are developed by Castle Biosciences. | |
| junotherapeutics.com | 2013 | Seattle, United States | $316.67M | 520 | CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | |
| unitybiotechnology.com | 2016 | San Francisco, United States | $206M | – | Therapeutics for aging diseases are developed by targeting senescent cells. | |
| unilabs.com | 2000 | Geneva, Switzerland | – | – | Diagnostic services are provided through laboratories and radiology units. | |
| celsiustx.com | 2018 | Cambridge, United States | $148M | 50 | Single-cell RNA and genomic analysis for precision therapeutics are provided. | |
| intelliatx.com | 2014 | Cambridge, United States | $85.02M | 526 | Therapeutics using CRISPR/Cas9 are developed for various diseases. | |
| voyagertherapeutics.com | 2014 | Cambridge, United States | $105M | 183 | Gene Therapy to treat CNS diseases such as Parkinson’s disease, ALS. |
Detailed competitors of OmniSeq
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Omniseq
Complete news archive for OmniSeq
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to OmniSeq
10 companies that operate in the same segment as OmniSeq (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about OmniSeq
OmniSeq was founded in 2015 and raised its 1st funding round 2 years after it was founded.
OmniSeq is headquartered in Buffalo, United States. It is registered at Buffalo, New York, United States.
OmniSeq is a funded company, having raised a total of $8.89M across 5 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $10M, raised on Aug 2017.
OmniSeq offers a suite of precision medicine solutions to physicians that claims to combine genomic data with information technology. The companys OmniSeq Target for lung cancer offers genomic sequencing services that can be ordered online by the physician. Its OmniSeq Connect is a web-based testing order entry that can be integrated into EHR and offers payment verification, coordination of specimen collection, access to testing reports online, and mobile and email updates. The companys OmniSeq Genomic Network is a physician network that offers access to molecular testing for cancer, access to molecular clinical trials tool and genomic network database.
OmniSeq's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
OmniSeq offers OmniSeq INSIGHT.
OmniSeq has 2 investors. Key investors include LabCorp, and Hitachi High-Tech Corporation.
OmniSeq operates through Omniseq, Inc..